| Alternative Name: | WSL-1, Apo-3, LARD, TRAMP, TR3, TNFRSF 12, TNFRSF 25, Death receptor 3 |
| |
| MW: | ~55kDa (under reducing conditions). |
| |
| Source: | Produced in HEK 293 cells. The cysteine-rich region of human DR3 (aa 25-199) is fused to the Fc portion of human IgG1. |
| |
| UniProt ID: | Q93038 |
| |
| Concentration: | 1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Bio Whittaker). |
| |
| Specificity: | Binds human TL1A. |
| |
| Application Notes: | Can be used together with anti-human IgG1 PAb to detect TL1A. |
| |
| Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. After reconstitution, it is recommended to make appropriate aliquots and to store them at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Scientific Background: | The DR3 receptor (WSL-1, Apo-3, LARD, TRAMP, TR3) is a member of the tumor necrosis factor receptor (TNF-R) family. DR3 is a type I transmembrane receptor. It is 339 aa long and contains 4 extracellular cysteine-rich motifs in its extracellular domain, while its cytoplasmic region contains a death domain. DR3 is abundantly expressed on thymocytes and T and B lymphocytes. Overexpression of DR3 mediates activation of nuclear factor NF-κB and induces apoptosis. Besides the induction of apoptosis, DR3 has been reported to regulate negative selection during thymocyte development. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
